First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Razak, Albiruni R. A.
Soerensen, Morten Mau
Mahipal, Amit
Shacham, Sharon
Yau, Cindy Y. F.
Lassen, Ulrik Niels
McCauley, Dilara
Cooksey, Jennifer
Tan, David Shao Peng
Saint-Martin, Jean-Richard
Landesman, Yossi
Pond, Gregory
Oza, Amit M.
Kauffman, Michael
Siu, Lillian L.
Mirza, Mansoor Raza
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Karyopharm Therapeut, Newton, MA USA
[5] Ozmosis Res Inc, Toronto, ON, Canada
[6] Rigshosp, DK-2100 Copenhagen, Denmark
[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors
    Devalingam Mahalingam
    Wael Harb
    Amita Patnaik
    Andrea Bullock
    Randolph S. Watnick
    Melanie Y. Vincent
    Jian Jenny Chen
    Suming Wang
    Harold Pestana
    Judy Chao
    James Mahoney
    Michael Cieslewicz
    Jing Watnick
    Communications Medicine, 4
  • [22] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
    Doi, T.
    Murakami, H.
    Wan, K.
    Miki, M.
    Kotani, H.
    Sakamoto, N.
    Yamamoto, N.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
    Dolly, S. O.
    Albanell, J.
    Kraeber-Bodere, F.
    Banerji, U.
    Bahleda, R.
    Garcia, M. Martinez
    Xu, Z. X.
    Guarin, E.
    Tessier, J.
    Shochat, E.
    Deutsch, J.
    Blotner, S.
    Meresse, V.
    Soria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)
    Chen, Christine I.
    Gutierrez, Martin
    Brown, Peter de Nully
    Gabrail, Nashat
    Baz, Rachid
    Reece, Donna E.
    Savona, Michael
    Trudel, Suzanne
    Siegel, David S.
    Mau-Sorensen, Morten
    Kuruvilla, John
    Byrd, John C.
    Shacham, Sharon
    Rashal, Tami
    Yau, Cindy Y. F.
    McCauley, Dilara
    Landesman, Yosef
    Klebanov, Boris
    Pond, Greg
    Oza, Amit M.
    Kauffman, Michael
    Mirza, Mansoor R.
    BLOOD, 2013, 122 (21)
  • [26] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
    Perets, Ruth
    Geva, Ravit
    McKean, Meredith
    Goutopoulos, Andreas
    Erez, Omri
    Phadnis, Monica
    Youssoufian, Hagop
    Schwartz, Brian E.
    Kansra, Vikram
    Fattaey, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS)
    Lewin, Jeremy
    Malone, Eoghan
    Al-Ezzi, Esmail
    Fasih, Samir
    Pedersen, Pernille
    Accardi, Sarah
    Gupta, Abha
    Razak, Albiruni Abdul
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 360 - 367
  • [29] A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Naylor, Gregory
    Bashir, Saira
    Yan, Xiangfei
    Burke, David
    Plummer, Elizabeth Ruth
    Evans, T. R. Jeffry
    Coyle, Victoria M.
    Clive, Sally
    McGuigan, Lesley
    Heinzmann, Kathrin
    Halbert, Gavin
    Veal, Gareth
    Tiplady, Eleanor
    Barnett, Shelby
    Yalla, Krishna
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Coyle, Victoria
    Evans, T. R. Jeffry
    Plummer, Elizabeth Ruth
    Clive, Sally
    McGuigan, Lesley
    Roxburgh, Patricia
    Haris, Noor Md
    Symeonides, Stefan N.
    Naylor, Gregory
    Bashir, Saira
    Stanley, Barbara
    Godfrey, Lisa
    Elliott, Moira
    Halbert, Gavin
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345